Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Top Cited Papers
- 1 February 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 6 (2), 202-216
- https://doi.org/10.1158/2159-8290.cd-15-0283
Abstract
T cell–mediated immunotherapies are promising cancer treatments. However, most patients still fail to respond to these therapies. The molecular determinants of immune resistance are poorly understood. We show that loss of PTEN in tumor cells in preclinical models of melanoma inhibits T cell–mediated tumor killing and decreases T-cell trafficking into tumors. In patients, PTEN loss correlates with decreased T-cell infiltration at tumor sites, reduced likelihood of successful T-cell expansion from resected tumors, and inferior outcomes with PD-1 inhibitor therapy. PTEN loss in tumor cells increased the expression of immunosuppressive cytokines, resulting in decreased T-cell infiltration in tumors, and inhibited autophagy, which decreased T cell–mediated cell death. Treatment with a selective PI3Kβ inhibitor improved the efficacy of both anti–PD-1 and anti–CTLA-4 antibodies in murine models. Together, these findings demonstrate that PTEN loss promotes immune resistance and support the rationale to explore combinations of immunotherapies and PI3K–AKT pathway inhibitors. Significance: This study adds to the growing evidence that oncogenic pathways in tumors can promote resistance to the antitumor immune response. As PTEN loss and PI3K–AKT pathway activation occur in multiple tumor types, the results support the rationale to further evaluate combinatorial strategies targeting the PI3K–AKT pathway to increase the efficacy of immunotherapy. Cancer Discov; 6(2); 202–16. ©2015 AACR. See related commentary by Rizvi and Chan, p. 128. This article is highlighted in the In This Issue feature, p. 109Keywords
Other Versions
This publication has 51 references indexed in Scilit:
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal CancerPLOS ONE, 2013
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell TherapyPLOS ONE, 2013
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletionNature Medicine, 2013
- Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesisGenes & Development, 2012
- Endogenous viruses: insights into viral evolution and impact on host biologyNature Reviews Genetics, 2012
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAFOncogene, 2011
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTORProceedings of the National Academy of Sciences of the United States of America, 2008
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006